Event Recap: The Alzheimer’s Disease Genetics Consortium (ADGC) 10-Year Symposium

Last month, on November 12 and 13, the Alzheimer’s Disease Genetics Consortium (ADGC) 10-Year Symposium took place at the Inn at Penn in Philadelphia, PA. The event was sponsored by the Perelman School of Medicine and the Department of Pathology and Laboratory Medicine, and it was organized by ADGC, Penn Neurodegeneration Genomics Center (PNGC) and […]

The State of Alzheimer’s Disease Genetics Research: A Discussion with Dr. Gerard Schellenberg

  • Human genetics helps us understand the biology of Alzheimer’s and identify drug targets.
  • Improvements in technology such as sequencing and gene therapy are promising.
  • Large sample sizes and rich phenotypes are critical to finding new AD genes.
  • Data visualization and outreach will encourage closer collaboration among the research community.

Largest GWAS To Date Implicates Abeta, Tau, Immunity and Lipid Processing in LOAD

The Alzheimer’s Disease Genetics Consortium (ADGC) and and the International Genomics of Alzheimer’s Project (IGAP) performed the largest genetic wide association study (GWAS) to date to discover risk loci for LOAD. Their meta-analysis implicates Abeta, Tau, immunity and lipid processing. The paper on Alzheimer’s disease genetic association has been published on bioRxiv and can be […]


PNGC is pleased to announce the release of the INFERNO (INFERing the molecular mechanisms of NOncoding genetic variants) method (http://inferno.lisanwanglab.org). Since the majority of variants that genome-wide association studies (GWAS) identify are outside of protein-coding genes and may be proxies of truly causal variants that are inherited together in linkage disequilibrium (LD), there is a […]